Take that Ed­i­tas: CRISPR Ther­a­peu­tics and col­leagues win a Eu­ro­pean round in the IP tug-of-war over gene edit­ing tech

Still boil­ing over the lat­est patent de­ci­sion on CRISPR/Cas 9 IP in the US, CRISPR Ther­a­peu­tics $CR­SP says its sci­en­tif­ic founders have won a broad patent cov­er­ing their work in Eu­rope.

The Eu­ro­pean Patent Of­fice has come through with patent no. 13793997, says the biotech. And the UK’s patent of­fice fol­lowed through, tak­ing the same po­si­tion.

“We and the li­cen­sors of these foun­da­tion­al cas­es for CRISPR/Cas9 gene edit­ing have long ap­pre­ci­at­ed that Em­manuelle Char­p­en­tier, Jen­nifer Doud­na, and their doc­tor­al and post-doc­tor­al col­leagues pro­vid­ed es­sen­tial teach­ings that ef­fec­tive­ly en­abled and fa­cil­i­tat­ed the CRISPR field, which has al­lowed both re­searchers and gene edit­ing com­pa­nies to eas­i­ly and pre­cise­ly mod­u­late tar­get DNA se­quences in any cell type and set­ting, in­clud­ing in hu­man cells for po­ten­tial ther­a­peu­tic ap­pli­ca­tions,” said Dr. Tyler Dy­lan-Hyde, the chief le­gal of­fi­cer of CRISPR Ther­a­peu­tics. “We al­so ap­pre­ci­ate that, de­spite at­tempts by third par­ties try­ing to de­lay or pre­vent these grants through TPOs or po­ten­tial op­po­si­tions, patent of­fices are be­gin­ning to rec­og­nize both the fun­da­men­tal sig­nif­i­cance of the teach­ings by the Char­p­en­tier-Doud­na team and their wide ap­plic­a­bil­i­ty to the CRISPR field. We look for­ward to pur­su­ing sim­i­lar find­ings in the U.S. un­der the first-to-in­vent sys­tem, and through­out the ap­prox­i­mate­ly 80 oth­er coun­tries our fil­ings cov­er world­wide, all of which are on a first-to-file pri­or­i­ty sys­tem.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER